ERBB2 and urinary bladder cancer: Although there was no relationship between the cytology results and the HER2/neu levels in patients with bladder cancer, those with positive NMP22 were found to have a significantly higher urinary HER2/neu/urinary creatinine ratio (0.55±0.63, 0.35±0.61, p=0.038) and significantly lower serum HER2/neu levels (10.05±24.95ng/mL, 1.63±1.25ng/mL, p=0.015) (Table-3).